Want to see FR:ALERS full AI Analyst Report?

Eurobio-Scientific SA (ALERS) Price & Analysis

1 Followers

ALERS Stock Chart & Stats

€24.15

€0.00(0.00%)

At close: Jan 09 4:00 PM EST

€24.15

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€20.40 - €25.95

Previous CloseN/A

Volume66.00

Average Volume (3M)968.00

Market Cap

€214.12M

Enterprise Value€219.22M

Total Cash (Recent Filing)€20.66M

Total Debt (Recent Filing)€16.02M

Price to Earnings (P/E)45.5

Beta-0.26

Next Earnings

Oct 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.47

Shares Outstanding10,248,871

10 Day Avg. Volume1,061

30 Day Avg. Volume968

Financial Highlights & Ratios

PEG Ratio2.53

Price to Book (P/B)1.36

Price to Sales (P/S)1.48

P/FCF Ratio39.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.13

Revenue Forecast (FY)€175.90M

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetLow leverage and a larger equity buffer materially improve financial resilience over the medium term. This reduces refinancing risk, supports investment in product development or targeted M&A, and gives management flexibility to navigate cyclical lab spending without immediate liquidity pressure.

Consistent Cash GenerationSustained positive operating and free cash flow provide a durable source of internal funding for R&D, working capital and selective capex. Even with recent deterioration, consistent cash generation reduces reliance on external financing and underpins longer-term operational stability.

Stable Revenue & Healthy Gross MarginsModest top-line growth plus mid-40s gross margins indicate durable product economics from test kits, reagents and distribution. Recurring consumable sales and instrument attach-rates support predictable revenue streams and margin base that can sustain reinvestment in diagnostics portfolio.

Bears Say

Eroded ProfitabilitySharp narrowing of operating and net margins lowers the company's earnings power and reduces internal funds for growth. Persistently thin margins increase vulnerability to pricing pressure, input cost volatility and compress capacity to invest in R&D or expand commercial reach.

Weakened Cash ConversionDeclining free cash flow and worse cash conversion mean less cash available for dividends, capex and strategic initiatives. Over a multi-quarter horizon, lower conversion raises the chance management must slow investments or seek external funding to support growth plans.

Volatile Returns On EquityWide historical swings in profitability and a near-zero recent ROE complicate capital allocation and investor visibility. Inconsistent returns make it harder to forecast sustainable shareholder value creation and raise the execution risk of long-term strategic initiatives.

ALERS FAQ

What was Eurobio-Scientific SA’s price range in the past 12 months?

Eurobio-Scientific SA lowest stock price was €20.40 and its highest was €25.95 in the past 12 months.

What is Eurobio-Scientific SA’s market cap?

Eurobio-Scientific SA’s market cap is €214.12M.

When is Eurobio-Scientific SA’s upcoming earnings report date?

Eurobio-Scientific SA’s upcoming earnings report date is Oct 13, 2026 which is in 103 days.

How were Eurobio-Scientific SA’s earnings last quarter?

Eurobio-Scientific SA released its earnings results on Apr 10, 2026. The company reported €0.248 earnings per share for the quarter, beating the consensus estimate of N/A by €0.248.

Is Eurobio-Scientific SA overvalued?

According to Wall Street analysts Eurobio-Scientific SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eurobio-Scientific SA pay dividends?

Eurobio-Scientific SA does not currently pay dividends.

What is Eurobio-Scientific SA’s EPS estimate?

Eurobio-Scientific SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eurobio-Scientific SA have?

Eurobio-Scientific SA has 10,248,871 shares outstanding.

What happened to Eurobio-Scientific SA’s price movement after its last earnings report?

Eurobio-Scientific SA reported an EPS of €0.248 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Eurobio-Scientific SA?

Currently, no hedge funds are holding shares in FR:ALERS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eurobio-Scientific SA

Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.